Harvard Health Blog
Ranitidine (Zantac) recall expanded, many questions remain
By: Joshua Gagne, PharmD, ScD, Contributor As anticipated, recall of the popular heartburn medicine ranitidine (Zantac) has expanded. But we still have more questions than answers. As I mentioned in my original blog post on this topic, the online pharmacy Valisure, which originally alerted the FDA to the issue, found what they called “extremely high levels” of the probable cancer-causing substance N-nitrosodimethylamine (NDMA) in ranitidine products.